Prevention of calcification of glutaraldehyde pretreated bovine pericardium through controlled release polymeric implants: studies of Fe3+, Al3+, protamine sulphate and levamisole
dc.contributor.author | Pathak, Yashwant V. | en_US |
dc.contributor.author | Boyd, James A. | en_US |
dc.contributor.author | Levy, Robert J. | en_US |
dc.contributor.author | Schoen, Frederick J. | en_US |
dc.date.accessioned | 2006-04-10T13:34:46Z | |
dc.date.available | 2006-04-10T13:34:46Z | |
dc.date.issued | 1990-11 | en_US |
dc.identifier.citation | Pathak, Yashwant V., Boyd, James, Levy, Robert J., Schoen, Frederick J. (1990/11)."Prevention of calcification of glutaraldehyde pretreated bovine pericardium through controlled release polymeric implants: studies of Fe3+, Al3+, protamine sulphate and levamisole." Biomaterials 11(9): 718-723. <http://hdl.handle.net/2027.42/28338> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6TWB-48HRJWD-JT/2/fe3fbbc74e3b9b1903836545fd6080cd | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/28338 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2128616&dopt=citation | en_US |
dc.description.abstract | Calcification is the principal cause of the clinical failure of bioprosthetic heart valves fabricated from glutaraldehyde pretreated porcine aortic valves or bovine pericardium. The present study investigated controlled-release implants for prevention of the calcification of glutaraldehyde pretreated bovine pericardium in a rat subdermal model. Either Al3+ and Fe3+ (inhibitors of the growth and dissolution rate of hydroxyapatite crystals), levamisole (alkaline phosphatase inhibitor) or protamine sulphate (charge modifier) were individually incorporated into various polymeric carriers (either silicone rubber. Polyurethane or silicone rubber-polyurethane copolymer). Polymeric implants were evaluated for in vitro release kinetics, which revealed that sustained drug release was obtained from 21 d to more than 90 d from various drug matrices. In vivo efficacy was studied by co-implanting the polymeric delivery systems with glutaraldehyde pretreated bovine pericardium for 21 d using a subdermal rat model; glutaraldehyde pretreated bovine pericardium calcium levels were quantitated by atomic absorption spectroscopy in the explanted tissues. Fe3+ and Al3+ polymeric implants were the most effective for inhibiting deposition of calcium mineral. Al3+ demonstrated 82% inhibition of calcification compared to controls and Fe3+ resulted in 80% inhibition of calcification. Specific histologie staining methods showed that Fe3+ and Al3+ were localized within the devitalized cells of the explanted glutaraldehyde pretreated bovine pericardium. No adverse effects on somatic growth or recipient bone morphology were noted following controlled-release drug administration. Controlled release of protamine sulphate or levamisole did not significantly inhibit glutaraldehyde pretreated bovine pericardium calcification. It is concluded that regional controlled release of Fe3+ or AI3+ inhibits glutaraldehyde pretreated bovine pericardium calcification in the rat subdermal model without adverse effects. | en_US |
dc.format.extent | 1396998 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Prevention of calcification of glutaraldehyde pretreated bovine pericardium through controlled release polymeric implants: studies of Fe3+, Al3+, protamine sulphate and levamisole | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Materials Science and Engineering | en_US |
dc.subject.hlbsecondlevel | Dentistry | en_US |
dc.subject.hlbsecondlevel | Biomedical Engineering | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI 48109-0576, USA | en_US |
dc.contributor.affiliationum | Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI 48109-0576, USA | en_US |
dc.contributor.affiliationum | Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI 48109-0576, USA | en_US |
dc.contributor.affiliationother | Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA | en_US |
dc.identifier.pmid | 2128616 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/28338/1/0000097.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0142-9612(90)90034-N | en_US |
dc.identifier.source | Biomaterials | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.